Ionis Pharmaceuticals Stock Slides 37% Over 8 Straight Down Days
A persistent slide in the biotech’s stock price prompts a closer look at the numbers behind the momentum.
Ionis Pharmaceuticals (IONS) stock has moved lower for 8 consecutive trading days, a cumulative loss of 37.0%. That streak has erased about $5.3 billion from the company’s market value, which now stands at about $9.0 billion.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
How The Streak Stacks Up Against The S&P 500
Here is how IONS stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | IONS | S&P 500 |
|---|---|---|
| 1D | -0.5% | -1.0% |
| 8D (Current Streak) | -37.0% | -0.6% |
| 1M (21D) | -25.6% | -0.7% |
| 3M (63D) | -27.7% | 5.9% |
| YTD 2026 | -31.2% | 8.9% |
| 2025 | 126.3% | 16.4% |
| 2024 | -30.9% | 23.3% |
| 2023 | 33.9% | 24.2% |
What do the fundamentals suggest about this sell-off?
The data points to significant profitability challenges. The company’s operating margin over the last twelve months is -33.3%, a sharp contrast to the S&P 500 median of 18.4%. IONS also has negative trailing earnings. This pressure appears to be company-specific, as the S&P 500 returned -0.6% over the same 8 trading days, meaning the streak is mostly this stock’s own story.
Such streaks are not unusual in the broader market. Currently, 38 S&P 500 stocks are on losing streaks of 3 days or more, while 37 are on winning streaks.
A streak is a signal, not a strategy.
An 8-day move draws attention, but it is not an instruction. It is simply information that momentum has been persistent in one direction, forcing market participants to re-evaluate their positions. The disciplined response is to weigh the business’s underlying performance against its new, lower price.
The financial metrics here provide a clear starting point for that assessment, framing the recent price action against the company’s fundamental picture.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Prefer the theme to this single name? Our ETF Scorecard shows how the biotech funds stack up. That way no single company’s next surprise decides the outcome.
IONS Has Fallen 52% From A Peak Before
A stock that falls day after day is a live lesson in what single name exposure feels like. IONS itself has fallen 52% from a peak within the past five years, and a fall like that lands very differently when one position carries too much of your wealth. Knowing what a repeat would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.
